Evidence map›Paper›PMID 36874750›Full record

ArticleCureus2023

Development of Liver Cancers as an Unexpected Consequence of Anabolic Androgenic Steroid Use.

Sameeha Khalid, Gieric Laput, Kamal Khorfan, Marina Roytman

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sameeha KhalidInternal Medicine, University of California San Francisco Fresno, Fresno, USA.
Gieric LaputGastroenterology and Hepatology, University of California San Francisco Fresno, Fresno, USA.
Kamal KhorfanGastroenterology and Hepatology, University of California San Francisco Fresno, Fresno, USA.
Marina RoytmanGastroenterology and Hepatology, University of California San Francisco Fresno, Fresno, USA.
California State University, Fresno · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the relationship between androgens and hepatocellular tumor development has been noted since 1975, cases involving hepatocellular carcinoma (HCC) or cholangiocarcinoma development in patients on chronic androgen therapy or anabolic androgenic steroid (AAS) use are few, and far between. We present three cases of patients who developed hepatic and bile duct malignancies in the setting of AAS use and testosterone supplementation, arising from a single tertiary referral center. Additionally, we review the literature for the mechanisms behind the possible androgen-mediated malignant transformation of these liver and bile duct tumors.

Indexed as

cholangiocarcinomadrug-induced liver injury (dili)hepatocellular carcinimahepatotoxicitytestosterone hormone

Identifiers

PMID36874750
PMCPMC9975287
OpenAlexW4318590023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.